medigraphic.com

2015, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (2)

Clinical Practice Guideline. Diagnosis and treatment of postmenopausal and perinemopausia

Alvarado-García A, Hernández-Quijano T, Hernández- Valencia M, Negrín-Pérez MC, Ríos-Castillo B, Valencia-Pérez GU, Vital-Reyes VS, Basavilvazo-Rodríguez MA, Torres-Arreola LP, Ortiz-Luna GF, Sánchez-Aguirre F, Montaño-Uscanga A

Language: Spanish
References: 22
Page: 214-225
PDF size: 116.34 Kb.


ABSTRACT

Post-menopause is the period of life where a deep decline occurs in circulating estrogen levels, inducing the appearance of psycho and somatic symptoms. The classifi cation to understand the chronology of reproductive aging in women (known as STRAW) determines the clinical and endocrine changes contemplating menstrual cycles, symptoms, measurements of FSH, LH, inhibin B, anti-Mullerian hormone , and follicular account. The diagnosis of menopause is established by the absence of menstruation for 12 months or more. The most frequent clinical manifestations of the climacteric syndrome transition to menopause are: menstrual disorders, vasomotor symptoms (fl ushes and/or sweats) and genitourinary manifestations. The assessment of women in the peri- or postmenopause aims to develop: cervicovaginal cytology , lipid profi le , serum glucose, basal Mammography at least a year before, pelvic ultrasound, urinalysis, serum TSH, Densitometry in patients older than 60 years if there is no recourse can be applied and FRAX. Drug therapy for the treatment of disorders of the transition to menopause or menopause is divided into: Hormone Therapy (HT) based estrogens and progestin hormone not being the most recommended the serotonin reuptake inhibitors and norepinephrine , clonidine, gabapentin or veralipride.


REFERENCES

  1. American Associaton of Clinical Endocrinologists Medical guidelines for clinical practice for the diagnosis and treatment of menopause (AACE). Endocrine Practice 2011.Goodman Neil F, FACE; Rhoda H Cobin, MACE; Ginzburg SB; Katz IA, FACE; Woode DE;17(Suppl 6):1-26.

  2. Sarrafzadegan N, Khosravi B, Esmaillzadeh A, Sadeghi MR, Asgary S. The Association betwen Hypertiglyceridemia Waist Phenotype Menopause, and cardiovascular risk factors. Arch of Iranian Medicine. 2013;16(3):161-3.

  3. Secretaría de Salud. Norma Ofi cial Mexicana NOM- 035-SSA2-2002, Prevención y control de enfermedades en la perimenopausia y postmenopausia de la mujer. Criterios para brindar la atención médica. México: Secretaría de Salud; 2002.

  4. The North American Menopause Society. Management of osteopososis in postmenopausal women: 2010 position statement of the nort American Menopause Society. Menopause: 2010;17(1):23-4.

  5. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. STRAW + 10 Collaborative Group Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfi nished agenda of staging reproductive aging. Menopause. 2012;19 (4):1-9.

  6. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society. 2012;19(3):257-71.

  7. Instituto Nacional de Estadística y Geografía (INEGI). Los adultos mayores en México. Perfi l sociodemográfi co al inicio siglo XXI. Disponible en http://www.inegi.gob.mx/prod_serv/contenidos/ espanol/bvinegi/produductos/censos/poblacion/ adultosmayores/Adultos_mayores_web2.pdf.

  8. Legorreta D, Montaño JA, Hernández I, Salinas C, Hernández-Bueno JA; on behalf of the Amec Research Committee. Age at menopause, motives for consultation and symptoms reported by 40-59-yearold Mexican women. Climacteric. 2012 Aug 13.

  9. Avenell A, Gillespie WJ, Gillespie LD, Connell DO. Vitamin D and vitamin D analoues for preventing fractures associated with involutional and post menopausal osteoporosis. Cochrane Database of systematic review; 2009.

  10. Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF et al . Update 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climateric. 2013;16(3):316-37.

  11. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008. Position statement of the North American Menopause Society. Menopause. 2008;15(4): 584-603.

  12. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society. 2007;14(2):1-17.

  13. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society, Menopause 2003;10:113-32.

  14. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Sturdee DW, Pines A on behalf of the International Menopause Society Writing Group. Climacteric. 2011;14:302-20. Disponible en http://www.imsociety. org/pdf_fi les/ims_recommendations/updated_ims_ recommendations_on_postmenopausal_hormone_ therapy_and_preventive_strategies_for_midlife_ health_01_06_11.pdf.

  15. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormony therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of systematic Reviews 2012. Issue 8, Art. No.:CD000402.doi:10.1002/14651858.CD000402. pub4.

  16. Formoso G, Perrone E, Maltoni S, Balduzzi S, D’Amico R, Bassi C, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Rev Med Inst Mex Seguro Soc. 2015;53(2):214-25 225 Alvarado-García A et al. Diagnóstico y tratamiento de la perimenopausia y la postmenopausia Database of Systematic Reviews. In: The Cochrane Library, 2013; Issue 7, Art. No. CD008536. DOI

  17. Schindler A. Differential effects of progestins. European Progestin. Maturitas. 2003;10 (46):s3-s5.

  18. Levis S, Strickman-Stein N, Doerge DR, Krischer J. Design and baseline characteristics of the soy phytoestrogens as remplacement estrogens (SPARE) Study-A clinical trial of the effects of soy isofl avones in menopausal women. Contemp Clin Trials. 2010;31(4): 293-302.

  19. Lilue M, Palacios S. Tratamiento no-hormonal de los síntomas vasomotores durante la menopausia: papel de la desvenlafaxina. Ginecol Obstet Mex. 2009; 77(10):475-81.

  20. Basavilvazo-Rodríguez A, Bravo-Rodríguez LM, Carranza-Lira S, Celis-González C, Hernández Marín I et al. Consenso de la Asociación Mexicana para el Estudio del Climaterio para la indicación de veraliprida a pacientes con síntomas vasomotores. Ginecol Obstet Mex. 2012;80(7):467-72.

  21. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefl er LA, et al. Side effects of phytoestrogens: A mertaanalysis of randomized trials. The American Journal of Medicine. 2009;122(10):940-6.

  22. The Society of Obstetricians and Gynecologists (Canada). Clinical Practice Guideline. Menopause and osteoporosis (Update 2009). Journ Obst Gynec Can. 2009:S1-S48.




2020     |     www.medigraphic.com